08/21/2024 | News release | Distributed by Public on 08/21/2024 13:18
Around the world, life-saving drugs remain too expensive for too many. BiosanaPharma is working to change that. The company manufactures biosimilars-a pharmaceutical product that is almost identical to a product that is manufactured by a different company. By creating competition, biosimilars can make these medicines available to the public more affordably. The process of continuous biomanufacturing, however, involves a dizzying and intricate array of equipment.
That's why BiosanaPharma uses CONNECT data services to aggregate data from all its equipment and share it with trusted partners. Together, with the right tools, and right partners, BiosanaPharma is optimizing the biomanufacturing process and producing essential drugs at an affordable price.
"The future of biopharma is 'lights out' continuous end-to-end processing. The cost of goods of antibodies will decrease by a factor 10 in the next decade because of innovation."
- Maarten Pennings,
CTO, BiosanaPharma